ELECTOR · Project

Home Monitoring Platform That Replaces Hospital Visits for Arthritis Patients

healthPilotedTRL 6

Imagine if people with rheumatoid arthritis could skip most of their hospital check-ups and instead do their blood tests and joint assessments from home using a simple device and a website. That's exactly what ELECTOR built — a home kit with point-of-care testing devices and an online clinic where patients report their symptoms, and doctors see the results directly in the medical record. It was tested with real patients across Denmark, the UK, and the Czech Republic, proving that many routine outpatient visits can be safely replaced.

By the numbers

consortium partners

countries involved (CZ, DK, NL, UK)

countries where device validation was completed

SMEs in consortium

50%

industry partner ratio

total project deliverables

The business problem

What needed solving

Rheumatology clinics are overwhelmed by growing numbers of chronic patients who need regular monitoring — blood tests, joint assessments, symptom tracking — but most of these check-ups don't require physical presence. Patients waste time traveling to hospitals for routine visits, while clinics waste capacity on appointments that could be handled remotely. There is no integrated solution that combines home-based lab testing with digital symptom reporting and feeds results directly into hospital records.

The solution

What was built

A complete eHealth solution including point-of-care biochemistry devices for home blood testing, a web-based platform for patient self-assessment of symptoms and joint status, and a virtual outpatient clinic that integrates all collected data directly into electronic patient records. The system was validated through clinical pilot testing across Denmark, the UK, and the Czech Republic.

Audience

Who needs this

Telemedicine platform companies expanding into chronic disease managementPoint-of-care diagnostic device manufacturers seeking validated home-use applicationsHospital networks and rheumatology departments looking to reduce outpatient visit volumesHealth insurance companies interested in cost-effective chronic disease monitoringDigital health startups building remote patient monitoring solutions

Business applications

Who can put this to work

Digital Health / Telemedicine

SME

Target: Telemedicine platform providers and remote patient monitoring companies

If you are a telemedicine company looking to expand into chronic disease management — this project developed a validated eHealth platform combining point-of-care biochemistry devices with web-based symptom reporting, tested in clinical pilots across 3 countries. The virtual outpatient clinic model was validated with real patients and integrated directly into hospital records, giving you a proven blueprint to build or license.

Medical Devices

mid-size

Target: Point-of-care diagnostic device manufacturers

If you are a medical device company making portable testing equipment — this project validated home-use biochemistry devices against hospital laboratory standards in Denmark, the UK, and the Czech Republic. Device approval and reliability testing were completed across all 3 countries, with prototype production and distribution procedures proven sufficient for clinical trial use.

Hospital Management / Healthcare Providers

enterprise

Target: Rheumatology clinics and hospital networks managing chronic patients

If you run a rheumatology outpatient clinic struggling with growing patient volumes — this project demonstrated a virtual outpatient clinic that can substitute a large proportion of conventional visits. User analyses with both patients and healthcare professionals confirmed acceptance, and pilot testing across 3 countries showed the model works in different healthcare systems.

Frequently asked

Quick answers

What would it cost to implement a similar remote monitoring system?

The project's EU contribution amount is not available in the dataset. However, the consortium of 8 partners across 4 countries developed and validated the full solution including devices, software platform, and clinical protocols. Implementation costs would depend on scale and regulatory pathway in your market.

Can this scale beyond rheumatology to other chronic conditions?

The platform was designed for rheumatoid arthritis specifically, combining biochemistry testing with joint assessment questionnaires. The underlying architecture — point-of-care devices linked to a web platform feeding into patient records — is a model that could be adapted for other chronic diseases requiring regular blood work and symptom tracking.

What is the IP situation and can this technology be licensed?

The consortium includes 4 industry partners and 3 SMEs alongside universities, suggesting shared IP arrangements. The coordinator is Region Hovedstaden (Capital Region of Denmark, a public entity). Licensing discussions would need to go through the consortium partners who developed the device and software components.

Has this been tested with real patients in clinical settings?

Yes. The project completed clinical pilot testing, user analysis testing, and a virtual outpatient clinic study across Denmark, the UK, and the Czech Republic. Device validation and reliability testing were performed against local biochemistry standards in all 3 countries.

Does the platform integrate with existing hospital IT systems?

Based on the project objective, the solution provides integrated and direct collection of data into patient notes. The platform was designed to feed directly into existing electronic health records, which was part of the clinical validation process.

What regulatory approvals does the device have?

Device approval and validation procedures were completed, with reliability testing against local biochemistry standards in Denmark, the UK, and the Czech Republic. Prototype production, handling, and distribution procedures were confirmed sufficient for small-scale clinical trials. Full regulatory approval status for commercial use is not specified in the available data.

Is there ongoing support or further development planned?

The project reported that future trials preparation was completed, leading to the initiation of new collaborative research projects. This suggests active follow-up work, though the ELECTOR project itself closed in September 2018.

Consortium

Who built it

The ELECTOR consortium brings together 8 partners from 4 countries (Denmark, UK, Czech Republic, Netherlands), with a healthy 50% industry ratio — 4 industry partners including 3 SMEs alongside 2 universities and 1 research organization. This balanced mix means the technology was developed with commercial viability in mind from the start. The coordinator, Region Hovedstaden (Capital Region of Denmark), is one of Europe's largest hospital authorities, providing direct access to clinical environments for testing. The multi-country validation across 3 different healthcare systems (Danish, British, Czech) strengthens the case for cross-border deployability.

REGION HOVEDSTADENCoordinator · DK
PERCUROS BVparticipant · NL
SYDDANSK UNIVERSITETparticipant · DK
PHILIPS ELECTRONICS NEDERLAND BVparticipant · NL
ATONOMICS ASparticipant · DK
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORDparticipant · UK

How to reach the team

The coordinator is Region Hovedstaden (Capital Region of Denmark). Contact through SciTransfer for a warm introduction to the project team.

Order a report on this consortium See REGION HOVEDSTADEN profile →

Next steps

Talk to the team behind this work.

Want to explore licensing the ELECTOR platform or devices for your telemedicine business? SciTransfer can connect you directly with the right consortium partner — contact us for a one-page brief.

Order a report on this topic More in Health & Biomedical